26.10.2023 22:30:06 - dpa-AFX: GNW-Adhoc: Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023
Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023
Mont-Saint-Guibert, Belgium - October 26, 2023, 10:30pm CET / 4:30pm ET - Nyxoah
SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical
technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced
that the Company will release financial results for the third quarter of 2023 on
Wednesday, November 8, 2023, after market close. Company management will host a
conference call to discuss financial results that day beginning at 10:30pm CET /
4:30pm ET.
A webcast of the call will be accessible via the Investor Relations page of the
Nyxoah website or through this link: Nyxoah's Q3 2023 earnings call webcast
(https://edge.media-server.com/mmc/p/5tvtajxd/). For those not planning to ask a
question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah's Q3 2023
earnings call
(https://register.vevent.com/register/BIf7f85a84dfcc481b932b1fc8e8fbae95). After
registering, an email will be sent, including dial-in details and a unique
conference call access code required to join the live call. To ensure you are
connected prior to the beginning of the call, the Company suggests registering a
minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the
call.
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless
and battery-free hypoglossal neurostimulation therapy for OSA, the world's most
common sleep disordered breathing condition that is associated with increased
mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision
that OSA patients should enjoy restful nights and feel enabled to live their
life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system
received its European CE Mark in 2019. Following the positive outcomes of the
BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its
therapeutic indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors' therapy. Additionally, the Company is
currently conducting the DREAM IDE pivotal study for FDA and U.S.
commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com (mailto:david.demartino@nyxoah.com)
+1 310 310 1313
Â